Locations:
SearchAdvertisement
Two-year event-free survival comparable to matched sibling donor myeloablative transplant
First-in-human trials of CRISPR-Cas12a gene editing demonstrate safety and meaningful event-free survival
Multicenter effort aims to standardize information about diagnosis and early management
Variables affect nuances of the conversation
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
First in-human trial using CRISPR/CASP 12 for gene editing in sickle cell disease
A closer look at training, scholarship and opportunity within this sub subspecialty
Complex, bidirectional interactions exist between cancer, therapy, toxicities and eating behaviors
Previous studies, trial aims and the potential role of immunotherapy
Can disulfiram boost the efficacy of chemotherapy in this patient population?
Highlighting the importance of a multidisciplinary approach to care
Advertisement
Advertisement